AU2012201568B2 — Combinations and modes of administration of therapeutic agents and combination therapy
Assigned to Abraxis Bioscience LLC · Expires 2014-07-31 · 12y expired
What this patent protects
A method of treating a proliferative disease in an individual comprising administering to the individual: a) An effective amount of a composition comprising nanoparticles comprising a taxane and an albumin, and b) An effective amount of at least one other chemotherapeutic agent, …
USPTO Abstract
A method of treating a proliferative disease in an individual comprising administering to the individual: a) An effective amount of a composition comprising nanoparticles comprising a taxane and an albumin, and b) An effective amount of at least one other chemotherapeutic agent, wherein said chemotherapeutic agent is selected from the group consisting of antimetabolites, platinum based agents, acylating agents, tyrosine kinase inhibitors, anthracycline antibiotics, vinca alkaloids, proteasome inhibitors, macrolides and topoisomerase inhibitors.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.